Highest-materiality recent filing
Inogen Q2 revenue $95.1M (+3% YoY); raises FY adjusted EBITDA guidance to ~$4.0M
Q2 revenue $95.1M (+3% YoY); international revenue $41.3M (+14.8% YoY).
Inogen appoints Andy Reding as COO effective July 6, 2026
Andy Reding appointed to newly created COO role, effective July 6, 2026.
Inogen shareholders approve 750,000-share equity plan increase; declassification vote fails
Class III directors Glenn Boehnlein and Mira Sahney elected with 17.3M and 13.3M votes for, respectively.
Inogen Q1 revenue up 3.4% to $85.1M; net loss widens to $8.3M
GAAP net loss of $8.3M vs $6.2M loss in Q1 2025; adjusted net loss $4.0M vs $2.9M.
Inogen appoints Vafa Jamali to board, enters cooperation agreement with Kent Lake
Vafa Jamali appointed as independent Class I director effective June 15, 2026 or 2026 annual meeting.
Inogen names Jason Richardson CFO, appoints CMO and VP Sales; reaffirms 2026 guidance
Jason Richardson appointed CFO effective April 6, 2026; previously CFO of Baxter's Health System & Technologies segment.
Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.
Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026
Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.
Inogen Q3 revenue $92.4M (+4% YoY); adj. EBITDA positive $2.3M; raises FY guidance
Revenue $92.4M, up 4% YoY; seventh consecutive quarter of mid-single-digit growth.
Inogen Q2 2025 revenue $92.3M (+4% YoY); raises full-year revenue guidance
Revenue $92.3M, up 4% YoY; sixth consecutive quarter of mid-single-digit growth.
Inogen appoints Mary Wright as CAO, designates EVP Yi Boyer as executive officer
Jennifer Yi Boyer designated as executive officer and Section 16 officer effective July 28, 2025; she serves as EVP, Enterprise Enablement and CHRO.
20.9M shares (77.87% of outstanding) present at the annual meeting.
Inogen Q1 2025 revenue $82.3M (+5.5% YoY); adjusted EBITDA turns positive
Total revenue $82.3M, up 5.5% YoY (7.1% constant currency) on higher B2B demand.
Inogen Q4 revenue up 5.5% to $80.1M; full-year revenue up 6.4%; operating loss narrows significantly
Q4 revenue $80.1M (+5.5% YoY); gross margin 45.3% (vs 37.1% YoY) on lower raw material costs and efficiencies.
Inogen appoints Mira Kirti Sahney to board; Tom West retires effective Jan 30, 2025
Mira Sahney appointed to Inogen board effective Jan 31, 2025 as Class III director; term expires at 2026 annual meeting.
Inogen partners with Yuwell; receives ~$27.2M investment for 9.9% stake at $10.36/share
Strategic collaboration with Jiangsu Yuyue to distribute respiratory products in US/Europe and expand into China.
Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance
Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.
Inogen receives FDA 510(k) clearance for SIMEOX 200, triggering $13M milestone payment
FDA cleared SIMEOX 200 for airway clearance and bronchial drainage in patients with chronic lung diseases.
Inogen Q3 revenue up 5.8% to $88.8M; adjusted EBITDA turns positive $0.5M
Revenue $88.8M (+5.8% YoY) driven by business-to-business gains; direct-to-consumer and rental revenue fell.
Inogen Q2 revenue up 6.1% to $88.8M; net loss narrows to $5.6M
Total revenue $88.8M (+6.1% YoY) driven by international and domestic B2B sales.
Inogen EVP & General Counsel Jason Somer separates effective July 19; enters transition agreement
Separation date July 19, 2024; role as EVP and General Counsel ended.
Inogen appoints Kevin Smith as GC and EVP Business Development; Jason Somer departs July 19
Jason Somer, EVP, General Counsel & Secretary, to separate from Inogen on July 19, 2024.
Inogen stockholders approve amended 2023 equity plan, elect directors at annual meeting
Stockholders approved Amended & Restated 2023 Equity Incentive Plan: 14,014,481 for, 2,868,882 against, 79,455 abstentions (2,335,280 broker non-votes).
Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA
Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.
Inogen Q1 revenue up 8.1% to $78M; net loss narrows from $20.3M to $14.6M
Revenue $78.0M (+8.1% YoY) driven by higher international and domestic B2B sales.
Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024
Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.
Inogen Q4 revenue $75.9M (-14% YoY); FY net loss $102.4M, adj EBITDA -$37.8M
Q4 revenue $75.9M vs $88.1M YoY; full-year revenue $315.7M vs $377.2M in 2022.
Inogen appoints Michael Bourque as CFO effective March 4, 2024
Michael Bourque appointed EVP, CFO and Treasurer; succeeds interim CFO Mike Sergesketter who stays for transition.
Inogen appoints Grégoire Ramade as Chief Commercial Officer effective Jan 2, 2024
Grégoire Ramade, previously SVP International Sales since Nov 2023, named CCO.
Inogen officer Nabil Shabshab separates; receives $1.4M severance, resigns from board
Shabshab's employment ended Nov 10, 2023; entered separation agreement on Nov 22, 2023.
Inogen names Kevin Smith President and CEO; new compensation includes $1.7M sign-on bonus
Kevin Smith appointed President and CEO effective Nov 10, 2023, succeeding Nabil Shabshab who departed same day.
Inogen Q3 revenue $84.0M, down 20.3% YoY; GAAP net loss $45.7M from $32.9M impairment
Total revenue $84.0M vs $105.4M in Q3 2022, down 20.3% YoY.
Inogen completes acquisition of Physio-Assist for ~$32M cash plus up to $13M earnout
Paid ~$32M cash at closing, subject to net debt adjustment; potential earnout up to $13M if FDA clearance within 4 years.
Kristin Caltrider steps down as CFO effective Sep 11, 2023 for personal reasons; no disagreement with company.
Inogen EVP and CCO George Parr departs; enters transition agreement with 12-mo salary continuation
George Parr separated as EVP and Chief Commercial Officer effective July 31, 2023.
Inogen Q2 revenue down 19% to $83.6M; net loss widens to $9.8M
Total revenue $83.6M, down 19.1% YoY; GAAP net loss $9.8M vs $3.4M loss year ago.
Inogen EVP and Chief Commercial Officer George Parr to separate by July 31, 2023
George Parr, EVP and Chief Commercial Officer, mutually agreed to separate from the Company on or before July 31, 2023.
Inogen assigns headquarters lease to Sonos, pays $395K; expects new Santa Barbara lease
Inogen assigns lease for 301 Coromar Drive, Goleta, CA headquarters to Sonos effective on or before Oct 1, 2023.
Inogen to acquire Physio-Assist for up to $45M; prelim Q2 rev $83-84M
Acquires Physio-Assist for ~$32M cash at closing plus up to $13M on FDA clearance milestones; total capped at $45M.
Inogen stockholders approve 2023 Equity Incentive Plan, elect directors at annual meeting
Stockholders approved 2023 Equity Incentive Plan, effective June 5, 2023, replacing 2014 Plan.
Inogen Q1 2023 revenue $72.2M, net loss $20.3M; sees positive adjusted EBITDA by Q4 2023
Total revenue $72.2M, down 10.2% YoY; rental revenue up 25.4% YoY.
Inogen board member Kristen Miranda resigns; Tom West appointed effective April 1, 2023
Kristen Miranda resigned as director effective March 31, 2023; not due to any disagreement with the company.
Q4 revenue $88.1M (+15.3% YoY); full-year revenue $377.2M (+5.4% YoY).
EVP Operations Bart Sanford to separate from Inogen by March 1, 2023
Bart Sanford, EVP Operations, will separate on or before March 1, 2023.
Inogen reports preliminary Q4 2022 revenue within prior guidance range
Preliminary Q4 revenue $87.5M-$88.5M, YoY growth 14.5%-15.8%.
Inogen abandons TAV ventilator program, expects $53.4M asset write-down in Q4 2022
Ceased development of TAV technology from New Aera; estimates $53.4M loss on disposal of intangible assets.
Inogen Q3 revenue rises 13.2% to $105.4M but swings to GAAP net loss of $9.5M
Total revenue $105.4M (+13.2% YoY); constant currency growth 14.5%.
Inogen Q2 revenue $103.4M (+1.8% YoY) but GAAP net loss $3.4M vs $5.1M income a year ago
Total revenue $103.4M, up 1.8% YoY (3.6% constant currency) and 28.6% sequentially from Q1; international sales and domestic rentals drove growth.
Inogen holds 2022 annual meeting; elects directors, ratifies auditor, approves pay
Class II directors elected: King (19.2M for, 114k withhold), Ladone (19.2M for, 114k withhold), Shabshab (14.6M for, 4.7M withhold).
Inogen Q1 2022 revenue down 7.5% YoY to $80.4M; net loss $0.62 per share
GAAP net loss $14.2M ($0.62/share); adjusted loss per share $0.39.
appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (“COO”) of the Company, effective July 6, 2026.
On January 31, 2025, the Board, upon recommendation of the Nominating and Governance Committee, appointed Mira Kirti Sahney to the Board, effective January 31, 2025.
On January 30, 2025, Thomas A. West notified Inogen, Inc. (“the Company”) of his resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of January 30, 2025.
the Company and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.
On May 6, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Kevin P. Smith to serve as Executive Vice President, Business Development, General Counsel and Secretary of the Company, effective July 22, 2024.
On July 2, 2024, Inogen, Inc. (the “Company”) and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.
Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024
On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.
On January 21, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”) of the Company, effective March 4, 2024.
On January 2, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Grégoire Ramade to serve as Chief Commercial Officer (“CCO”) of the Company, effective January 2, 2024.
Mr. Shabshab resigned from the Company’s board of directors, effective as of November 22, 2023
Mr. Shabshab’s role as an officer and employee of the Company ended effective November 10, 2023
Max materiality 0.80 · Median 0.65 · Most common event earnings